25 XP   0   0   10

Interpace Biosciences Inc
Buy, Hold or Sell?

Let's analyse Interpace together

PenkeI guess you are interested in Interpace Biosciences Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Interpace Biosciences Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Interpace Biosciences Inc

I send you an email if I find something interesting about Interpace Biosciences Inc.

Quick analysis of Interpace (30 sec.)










What can you expect buying and holding a share of Interpace? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-14.59
Expected worth in 1 year
$-76.78
How sure are you?
20.0%

+ What do you gain per year?

Total Gains per Share
$-62.19
Return On Investment
-4,288.8%

For what price can you sell your share?

Current Price per Share
$1.45
Expected price per share
$1.23 - $2.006
How sure are you?
50%

1. Valuation of Interpace (5 min.)




Live pricePrice per Share (EOD)

$1.45

Intrinsic Value Per Share

$-17.45 - $19.86

Total Value Per Share

$-32.04 - $5.27

2. Growth of Interpace (5 min.)




Is Interpace growing?

Current yearPrevious yearGrowGrow %
How rich?-$63m$4.1m-$67.1m-106.5%

How much money is Interpace making?

Current yearPrevious yearGrowGrow %
Making money-$21.9m-$14.9m-$7m-31.9%
Net Profit Margin-69.0%-36.2%--

How much money comes from the company's main activities?

3. Financial Health of Interpace (5 min.)




4. Comparing to competitors in the Diagnostics & Research industry (5 min.)




  Industry Rankings (Diagnostics & Research)  

What can you expect buying and holding a share of Interpace? (5 min.)

Welcome investor! Interpace's management wants to use your money to grow the business. In return you get a share of Interpace.

What can you expect buying and holding a share of Interpace?

First you should know what it really means to hold a share of Interpace. And how you can make/lose money.

Speculation

The Price per Share of Interpace is $1.45. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Interpace.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Interpace, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-14.59. Based on the TTM, the Book Value Change Per Share is $-15.55 per quarter. Based on the YOY, the Book Value Change Per Share is $-3.09 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Interpace.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-5.08-350.4%-5.08-350.4%-3.46-238.5%-4.89-337.5%-3.12-215.3%
Usd Book Value Change Per Share-15.55-1,072.2%-15.55-1,072.2%-3.09-212.8%-4.76-328.5%-2.28-157.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-15.55-1,072.2%-15.55-1,072.2%-3.09-212.8%-4.76-328.5%-2.28-157.5%
Usd Price Per Share1.04-1.04-7.47-2.59-2.54-
Price to Earnings Ratio-0.20--0.20--2.16--0.64--2.42-
Price-to-Total Gains Ratio-0.07--0.07--2.42--1.28--0.43-
Price to Book Ratio-0.07--0.07-7.84-1.75-1.60-
Price-to-Total Gains Ratio-0.07--0.07--2.42--1.28--0.43-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.45
Number of shares689
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-15.55-4.76
Usd Total Gains Per Share-15.55-4.76
Gains per Quarter (689 shares)-10,711.79-3,282.28
Gains per Year (689 shares)-42,847.18-13,129.13
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-42847-428570-13129-13139
20-85694-857040-26258-26268
30-128542-1285510-39387-39397
40-171389-1713980-52517-52526
50-214236-2142450-65646-65655
60-257083-2570920-78775-78784
70-299930-2999390-91904-91913
80-342777-3427860-105033-105042
90-385625-3856330-118162-118171
100-428472-4284800-131291-131300

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%5.012.06.021.7%
Book Value Change Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%2.08.00.020.0%7.016.00.030.4%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%1.00.022.04.3%
Total Gains per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%2.08.00.020.0%7.016.00.030.4%

Fundamentals of Interpace

About Interpace Biosciences Inc

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis and prognosis of pancreatic cancer; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

Fundamental data was last updated by Penke on 2024-03-31 19:55:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Interpace Biosciences Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Interpace earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Interpace to the Diagnostics & Research industry mean.
  • A Net Profit Margin of -69.0% means that $-0.69 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Interpace Biosciences Inc:

  • The MRQ is -69.0%. The company is making a huge loss. -2
  • The TTM is -69.0%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-69.0%TTM-69.0%0.0%
TTM-69.0%YOY-36.2%-32.8%
TTM-69.0%5Y-70.6%+1.6%
5Y-70.6%10Y-63.0%-7.6%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-69.0%-8.1%-60.9%
TTM-69.0%-7.5%-61.5%
YOY-36.2%0.3%-36.5%
5Y-70.6%-2.2%-68.4%
10Y-63.0%-2.5%-60.5%
1.1.2. Return on Assets

Shows how efficient Interpace is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Interpace to the Diagnostics & Research industry mean.
  • -137.4% Return on Assets means that Interpace generated $-1.37 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Interpace Biosciences Inc:

  • The MRQ is -137.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -137.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-137.4%TTM-137.4%0.0%
TTM-137.4%YOY-38.9%-98.5%
TTM-137.4%5Y-62.3%-75.2%
5Y-62.3%10Y-39.1%-23.1%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-137.4%-1.7%-135.7%
TTM-137.4%-1.4%-136.0%
YOY-38.9%-1.2%-37.7%
5Y-62.3%-0.6%-61.7%
10Y-39.1%-0.9%-38.2%
1.1.3. Return on Equity

Shows how efficient Interpace is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Interpace to the Diagnostics & Research industry mean.
  • 0.0% Return on Equity means Interpace generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Interpace Biosciences Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-362.9%+362.9%
TTM-5Y-80.0%+80.0%
5Y-80.0%10Y-73.9%-6.1%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ--0.8%+0.8%
TTM--0.2%+0.2%
YOY-362.9%-0.2%-362.7%
5Y-80.0%-1.5%-78.5%
10Y-73.9%-2.5%-71.4%

1.2. Operating Efficiency of Interpace Biosciences Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Interpace is operating .

  • Measures how much profit Interpace makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Interpace to the Diagnostics & Research industry mean.
  • An Operating Margin of -12.1% means the company generated $-0.12  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Interpace Biosciences Inc:

  • The MRQ is -12.1%. The company is operating very inefficient. -2
  • The TTM is -12.1%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-12.1%TTM-12.1%0.0%
TTM-12.1%YOY-14.0%+1.9%
TTM-12.1%5Y-55.4%+43.3%
5Y-55.4%10Y-84.9%+29.6%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.1%-8.8%-3.3%
TTM-12.1%-0.7%-11.4%
YOY-14.0%4.0%-18.0%
5Y-55.4%2.1%-57.5%
10Y-84.9%-2.0%-82.9%
1.2.2. Operating Ratio

Measures how efficient Interpace is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Diagnostics & Research industry mean).
  • An Operation Ratio of 1.55 means that the operating costs are $1.55 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Interpace Biosciences Inc:

  • The MRQ is 1.548. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.548. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.548TTM1.5480.000
TTM1.548YOY1.850-0.302
TTM1.5485Y1.769-0.221
5Y1.76910Y0.914+0.855
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5481.315+0.233
TTM1.5481.320+0.228
YOY1.8501.240+0.610
5Y1.7691.275+0.494
10Y0.9141.235-0.321

1.3. Liquidity of Interpace Biosciences Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Interpace is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Diagnostics & Research industry mean).
  • A Current Ratio of 0.85 means the company has $0.85 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Interpace Biosciences Inc:

  • The MRQ is 0.851. The company is just not able to pay all its short-term debts. -1
  • The TTM is 0.851. The company is just not able to pay all its short-term debts. -1
Trends
Current periodCompared to+/- 
MRQ0.851TTM0.8510.000
TTM0.851YOY0.776+0.075
TTM0.8515Y1.089-0.238
5Y1.08910Y1.231-0.142
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8512.194-1.343
TTM0.8512.366-1.515
YOY0.7762.753-1.977
5Y1.0893.035-1.946
10Y1.2313.068-1.837
1.3.2. Quick Ratio

Measures if Interpace is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Interpace to the Diagnostics & Research industry mean.
  • A Quick Ratio of 0.35 means the company can pay off $0.35 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Interpace Biosciences Inc:

  • The MRQ is 0.352. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.352. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.352TTM0.3520.000
TTM0.352YOY0.298+0.054
TTM0.3525Y0.768-0.415
5Y0.76810Y0.972-0.204
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3521.272-0.920
TTM0.3521.346-0.994
YOY0.2981.564-1.266
5Y0.7681.933-1.165
10Y0.9722.129-1.157

1.4. Solvency of Interpace Biosciences Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Interpace assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Interpace to Diagnostics & Research industry mean.
  • A Debt to Asset Ratio of 4.95 means that Interpace assets are financed with 494.7% credit (debt) and the remaining percentage (100% - 494.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Interpace Biosciences Inc:

  • The MRQ is 4.947. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 4.947. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ4.947TTM4.9470.000
TTM4.947YOY0.893+4.054
TTM4.9475Y1.471+3.476
5Y1.47110Y1.062+0.409
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ4.9470.416+4.531
TTM4.9470.403+4.544
YOY0.8930.393+0.500
5Y1.4710.450+1.021
10Y1.0620.446+0.616
1.4.2. Debt to Equity Ratio

Measures if Interpace is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Interpace to the Diagnostics & Research industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Interpace Biosciences Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY8.331-8.331
TTM-5Y1.760-1.760
5Y1.76010Y2.462-0.702
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.606-0.606
TTM-0.563-0.563
YOY8.3310.617+7.714
5Y1.7600.637+1.123
10Y2.4620.705+1.757

2. Market Valuation of Interpace Biosciences Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Interpace generates.

  • Above 15 is considered overpriced but always compare Interpace to the Diagnostics & Research industry mean.
  • A PE ratio of -0.20 means the investor is paying $-0.20 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Interpace Biosciences Inc:

  • The EOD is -0.285. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.205. Based on the earnings, the company is expensive. -2
  • The TTM is -0.205. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.285MRQ-0.205-0.081
MRQ-0.205TTM-0.2050.000
TTM-0.205YOY-2.160+1.956
TTM-0.2055Y-0.638+0.433
5Y-0.63810Y-2.425+1.787
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD-0.285-0.268-0.017
MRQ-0.205-0.439+0.234
TTM-0.205-0.368+0.163
YOY-2.160-0.003-2.157
5Y-0.6384.755-5.393
10Y-2.4254.908-7.333
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Interpace Biosciences Inc:

  • The EOD is -0.815. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.584. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.584. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.815MRQ-0.584-0.230
MRQ-0.584TTM-0.5840.000
TTM-0.584YOY-3.558+2.974
TTM-0.5845Y-1.101+0.517
5Y-1.10110Y-2.300+1.199
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD-0.815-0.284-0.531
MRQ-0.584-0.534-0.050
TTM-0.584-1.432+0.848
YOY-3.558-2.547-1.011
5Y-1.101-1.847+0.746
10Y-2.300-2.293-0.007
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Interpace is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Diagnostics & Research industry mean).
  • A PB ratio of -0.07 means the investor is paying $-0.07 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Interpace Biosciences Inc:

  • The EOD is -0.099. Based on the equity, the company is expensive. -2
  • The MRQ is -0.071. Based on the equity, the company is expensive. -2
  • The TTM is -0.071. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.099MRQ-0.071-0.028
MRQ-0.071TTM-0.0710.000
TTM-0.071YOY7.840-7.911
TTM-0.0715Y1.750-1.821
5Y1.75010Y1.602+0.149
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD-0.0991.771-1.870
MRQ-0.0712.231-2.302
TTM-0.0712.222-2.293
YOY7.8403.239+4.601
5Y1.7503.450-1.700
10Y1.6024.040-2.438
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Interpace Biosciences Inc.

3.1. Institutions holding Interpace Biosciences Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2020-12-31BlackRock Inc2.8485011715400
2020-12-31Geode Capital Management, LLC0.789603247600
2020-12-31Tower Research Capital LLC0.04690.0002192919290
2021-03-31Retirement Group, LLC0.02430.0023100010000
2020-12-31Advisor Group Holdings, Inc.0.001205000
2020-12-31Wells Fargo & Co0.000602500
2020-12-31Morgan Stanley - Brokerage Accounts0.00010300
2021-03-31Hanson Mcclain Inc000-1429-100
2021-03-31Dimensional Fund Advisors, Inc.000-12864-100
2021-03-31UBS Group AG000-2946-100
2020-12-31Citadel Advisors Llc000-11858-100
2020-12-31Magnus Financial Group LLC000-48500-100
2020-12-31Penbrook Management LLC000-84400-100
2020-12-31Stonepine Capital Management Llc000-284730-100
2021-03-31Vanguard Group Inc000-80612-100
2020-12-31Glenmede Trust Co NA000-797-100
2021-03-31Squarepoint Ops LLC000-20755-100
Total 3.71120.0025152637-545962-357.7%

3.2. Funds holding Interpace Biosciences Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2021-03-31USAA Extended Market Index0.0120.0002494-142-22.327
2021-03-31NT Quality Small Cap Core0.000502200
2021-03-31NT Quality SCC US Fund - L0.000502200
2020-12-31NT Quality SCC Global Fund - NL00200
2020-12-31NT Quality SCC US Fund - NL00.0001200
Total 0.0130.0003542-142-26.2%

3.3. Insider Transactions

Insiders are holding 26.316% of the shares of Interpace Biosciences Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2021-02-26Kamin PeterBUY163603.08270108
2021-02-26Kamin PeterBUY148743.17220079
2021-02-26Kamin PeterBUY147263.08234805
2021-02-26Kamin PeterBUY83333.17124934
2021-02-26Kamin PeterBUY82523.08133186
2021-02-26Kamin PeterBUY28973.1741808
2021-02-26Kamin PeterBUY28623.0844670
2021-02-26Kamin PeterBUY149463.17253748
2015-11-25Melillo Gerald R JrSELL17480.77130173
2015-11-25Melillo Gerald R JrSELL7650.8131921
2015-11-25Melillo Gerald R JrSELL42620.78132686
2014-11-24Miao Graham GBUY6001.6542499
2014-11-24Miao Graham GBUY214001.6563899
2014-11-07Melillo Gerald R JrBUY50001.5850224
2014-11-05Lurker NancyBUY275001.74460903
2014-11-05Lurker NancyBUY275001.75488403
2014-11-05Lurker NancyBUY5001.72488903
2014-11-05Lurker NancyBUY5001.72489403
2014-11-05Lurker NancyBUY10001.6490403
2013-11-15Belle Gerald P.BUY74005.1471357

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Interpace Biosciences Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---15.547-15.5470%-3.086-80%-4.764-69%-2.284-85%
Book Value Per Share---14.594-14.5940%0.953-1632%0.608-2502%1.796-912%
Current Ratio--0.8510.8510%0.776+10%1.089-22%1.231-31%
Debt To Asset Ratio--4.9474.9470%0.893+454%1.471+236%1.062+366%
Debt To Equity Ratio----0%8.331-100%1.760-100%2.462-100%
Dividend Per Share----0%-0%-0%-0%
Eps---5.081-5.0810%-3.458-32%-4.894-4%-3.121-39%
Free Cash Flow Per Share---1.780-1.7800%-2.099+18%-2.801+57%-2.292+29%
Free Cash Flow To Equity Per Share---1.086-1.0860%-0.022-98%-0.130-88%-0.234-78%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--19.861--------
Intrinsic Value_10Y_min---17.447--------
Intrinsic Value_1Y_max---1.372--------
Intrinsic Value_1Y_min---2.562--------
Intrinsic Value_3Y_max---1.559--------
Intrinsic Value_3Y_min---7.038--------
Intrinsic Value_5Y_max--1.342--------
Intrinsic Value_5Y_min---10.758--------
Market Cap6266566.500+28%4494640.8004494640.8000%32283621.900-86%11193384.300-60%18806769.437-76%
Net Profit Margin---0.690-0.6900%-0.362-48%-0.706+2%-0.630-9%
Operating Margin---0.121-0.1210%-0.140+16%-0.554+359%-0.849+604%
Operating Ratio--1.5481.5480%1.850-16%1.769-13%0.914+69%
Pb Ratio-0.099-39%-0.071-0.0710%7.840-101%1.750-104%1.602-104%
Pe Ratio-0.285-39%-0.205-0.2050%-2.160+955%-0.638+212%-2.425+1085%
Price Per Share1.450+28%1.0401.0400%7.470-86%2.590-60%2.544-59%
Price To Free Cash Flow Ratio-0.815-39%-0.584-0.5840%-3.558+509%-1.101+88%-2.300+294%
Price To Total Gains Ratio-0.093-39%-0.067-0.0670%-2.421+3519%-1.276+1807%-0.431+544%
Quick Ratio--0.3520.3520%0.298+18%0.768-54%0.972-64%
Return On Assets---1.374-1.3740%-0.389-72%-0.623-55%-0.391-72%
Return On Equity----0%-3.6290%-0.8000%-0.7390%
Total Gains Per Share---15.547-15.5470%-3.086-80%-4.764-69%-2.284-85%
Usd Book Value---63072000.000-63072000.0000%4118000.000-1632%2626000.000-2502%12516900.000-604%
Usd Book Value Change Per Share---15.547-15.5470%-3.086-80%-4.764-69%-2.284-85%
Usd Book Value Per Share---14.594-14.5940%0.953-1632%0.608-2502%1.796-912%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---5.081-5.0810%-3.458-32%-4.894-4%-3.121-39%
Usd Free Cash Flow---7692000.000-7692000.0000%-9073000.000+18%-12105800.000+57%-13804400.000+79%
Usd Free Cash Flow Per Share---1.780-1.7800%-2.099+18%-2.801+57%-2.292+29%
Usd Free Cash Flow To Equity Per Share---1.086-1.0860%-0.022-98%-0.130-88%-0.234-78%
Usd Market Cap6266566.500+28%4494640.8004494640.8000%32283621.900-86%11193384.300-60%18806769.437-76%
Usd Price Per Share1.450+28%1.0401.0400%7.470-86%2.590-60%2.544-59%
Usd Profit---21958000.000-21958000.0000%-14943000.000-32%-20456200.000-7%-15482300.000-29%
Usd Revenue--31838000.00031838000.0000%41314000.000-23%30333200.000+5%46085700.000-31%
Usd Total Gains Per Share---15.547-15.5470%-3.086-80%-4.764-69%-2.284-85%
 EOD+6 -2MRQTTM+0 -0YOY+11 -215Y+11 -2110Y+8 -24

4.2. Fundamental Score

Let's check the fundamental score of Interpace Biosciences Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.285
Price to Book Ratio (EOD)Between0-1-0.099
Net Profit Margin (MRQ)Greater than0-0.690
Operating Margin (MRQ)Greater than0-0.121
Quick Ratio (MRQ)Greater than10.352
Current Ratio (MRQ)Greater than10.851
Debt to Asset Ratio (MRQ)Less than14.947
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-1.374
Total1/10 (10.0%)

4.3. Technical Score

Let's check the technical score of Interpace Biosciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.476
Ma 20Greater thanMa 501.501
Ma 50Greater thanMa 1001.329
Ma 100Greater thanMa 2001.194
OpenGreater thanClose1.450
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets15,979
Total Liabilities79,051
Total Stockholder Equity-63,072
 As reported
Total Liabilities 79,051
Total Stockholder Equity+ -63,072
Total Assets = 15,979

Assets

Total Assets15,979
Total Current Assets12,154
Long-term Assets3,825
Total Current Assets
Cash And Cash Equivalents 4,828
Net Receivables 5,032
Inventory 1,224
Other Current Assets 680
Total Current Assets  (as reported)12,154
Total Current Assets  (calculated)11,764
+/- 390
Long-term Assets
Property Plant Equipment 2,919
Intangible Assets 861
Other Assets 45
Long-term Assets  (as reported)3,825
Long-term Assets  (calculated)3,825
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities14,283
Long-term Liabilities64,768
Total Stockholder Equity-63,072
Total Current Liabilities
Short Long Term Debt 2,500
Accounts payable 1,050
Other Current Liabilities 858
Total Current Liabilities  (as reported)14,283
Total Current Liabilities  (calculated)4,408
+/- 9,875
Long-term Liabilities
Long term Debt 11,165
Capital Lease Obligations Min Short Term Debt2,426
Other Liabilities 5,219
Long-term Liabilities Other 5,219
Long-term Liabilities  (as reported)64,768
Long-term Liabilities  (calculated)24,029
+/- 40,739
Total Stockholder Equity
Common Stock405
Total Stockholder Equity (as reported)-63,072
Total Stockholder Equity (calculated)405
+/- 63,477
Other
Capital Stock405
Common Stock Shares Outstanding 4,297
Net Debt 8,837
Net Invested Capital -49,407
Net Tangible Assets -63,933
Net Working Capital -2,129
Property Plant and Equipment Gross 5,298



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-312002-12-312001-12-312000-12-31
> Total Assets 
270,225
302,671
190,939
219,623
224,705
200,306
201,636
179,554
149,036
109,776
124,389
113,379
78,447
69,064
115,906
67,712
41,778
53,598
48,442
51,540
45,681
38,427
15,979
15,97938,42745,68151,54048,44253,59841,77867,712115,90669,06478,447113,379124,389109,776149,036179,554201,636200,306224,705219,623190,939302,671270,225
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
80,360
71,583
62,709
44,866
19,165
4,240
19,808
17,721
16,510
14,122
12,166
12,154
12,15412,16614,12216,51017,72119,8084,24019,16544,86662,70971,58380,36000000000000
       Cash And Cash Equivalents 
109,000
160,043
66,827
113,288
96,367
90,827
45,221
99,185
90,074
72,463
62,711
64,337
52,783
45,639
23,111
8,310
602
15,199
6,068
2,321
3,372
3,064
4,828
4,8283,0643,3722,3216,06815,1996028,31023,11145,63952,78364,33762,71172,46390,07499,18545,22190,82796,367113,28866,827160,043109,000
       Short-term Investments 
4,907
7,387
5,834
1,344
13,131
6,807
69,463
7,800
159
3,822
227
127
92
103
107
106
0
0
0
0
0
0
0
0000000106107103921272273,8221597,80069,4636,80713,1311,3445,8347,3874,907
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
12,226
12,642
10,404
14,423
2,806
2,209
3,437
9,483
10,338
8,028
4,672
5,032
5,0324,6728,02810,3389,4833,4372,2092,80614,42310,40412,64212,22600000000000
       Other Current Assets 
14,229
37,711
32,186
21,543
15,883
14,078
10,528
7,558
4,511
1,587
3,294
3,670
6,066
6,563
7,225
7,943
1,429
1,172
2,170
3,851
2,722
3,413
680
6803,4132,7223,8512,1701,1721,4297,9437,2256,5636,0663,6703,2941,5874,5117,55810,52814,07815,88321,54332,18637,71114,229
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
33,019
6,864
6,355
71,040
48,547
37,538
33,790
30,721
35,030
31,559
26,261
3,825
3,82526,26131,55935,03030,72133,79037,53848,54771,0406,3556,86433,01900000000000
       Property Plant Equipment 
9,965
21,044
18,295
14,494
17,170
16,053
12,809
8,348
5,423
3,530
4,047
2,484
2,396
2,789
3,184
1,460
929
654
837
10,706
11,733
10,381
2,919
2,91910,38111,73310,7068376549291,4603,1842,7892,3962,4844,0473,5305,4238,34812,80916,05317,17014,49418,29521,0449,965
       Goodwill 
4,300
0
11,132
11,132
23,791
13,112
13,612
13,612
13,612
5,068
23,876
18,908
2,523
2,523
15,545
0
0
0
0
8,433
8,433
8,433
0
08,4338,4338,433000015,5452,5232,52318,90823,8765,06813,61213,61213,61213,11223,79111,13211,13204,300
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,057
0
0
0
0
0
0
0
0
000000001,05700000000000000
       Intangible Assets 
4,300
0
13,393
12,780
43,339
30,417
29,562
28,281
27,000
7,610
34,269
7,309
2,523
2,523
47,304
43,492
36,358
33,105
29,853
15,849
11,351
7,287
861
8617,28711,35115,84929,85333,10536,35843,49247,3042,5232,5237,30934,2697,61027,00028,28129,56230,41743,33912,78013,39304,300
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
4,318
1,945
1,043
5,007
3,595
251
31
31
3,934
4,426
160
45
451604,4263,93431312513,5955,0071,0431,9454,31800000000000
> Total Liabilities 
132,115
151,736
67,728
81,135
59,280
64,696
52,439
39,365
41,929
34,886
54,876
53,856
42,817
36,585
95,784
54,674
35,247
13,729
15,504
29,847
28,228
34,309
79,051
79,05134,30928,22829,84715,50413,72935,24754,67495,78436,58542,81753,85654,87634,88641,92939,36552,43964,69659,28081,13567,728151,736132,115
   > Total Current Liabilities 
131,283
151,436
67,728
81,135
59,280
64,696
44,554
29,188
31,360
24,880
43,328
46,078
36,390
31,400
33,578
23,373
16,241
8,091
8,492
17,292
18,233
15,682
14,283
14,28315,68218,23317,2928,4928,09116,24123,37333,57831,40036,39046,07843,32824,88031,36029,18844,55464,69659,28081,13567,728151,436131,283
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
27,154
1,164
7,908
0
0
0
0
0
0
0000007,9081,16427,15400000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
27,154
1,164
7,908
0
0
0
0
0
2,500
2,500000007,9081,16427,15400000000000000
       Accounts payable 
31,328
9,493
5,374
8,689
7,217
5,693
3,915
2,792
2,298
1,994
3,266
30,196
21,889
22,021
26,826
9,945
12,113
6,789
7,574
16,526
17,467
1,374
1,050
1,0501,37417,46716,5267,5746,78912,1139,94526,82622,02121,88930,1963,2661,9942,2982,7923,9155,6937,2178,6895,3749,49331,328
       Other Current Liabilities 
99,955
141,943
62,354
72,446
52,063
52,198
38,878
26,396
29,062
22,886
40,062
15,882
14,501
9,379
6,752
12,264
11,382
5,591
918
766
766
2,175
858
8582,1757667669185,59111,38212,2646,7529,37914,50115,88240,06222,88629,06226,39638,87852,19852,06372,44662,354141,94399,955
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
7,778
6,427
5,185
9,143
6,178
11,752
1,349
4,319
12,555
9,995
18,627
64,768
64,76818,6279,99512,5554,3191,34911,7526,1789,1435,1856,4277,77800000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
27,154
7,233
7,908
0
0
3,000
3,000
0
0
003,0003,000007,9087,23327,15400000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-27,154
-1,164
-7,908
0
0
4,096
4,744
4,274
2,426
2,4264,2744,7444,09600-7,908-1,164-27,15400000000000000
       Warrants
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
26,172
46,536
0
0
0046,53626,1720000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
7,778
0
0
25,909
17,890
3,844
1,349
2,693
9,555
9,995
6,018
5,219
5,2196,0189,9959,5552,6931,3493,84417,89025,909007,77800000000000
> Total Stockholder Equity
138,110
150,935
123,211
138,488
165,425
135,610
149,197
140,189
107,107
74,890
69,513
59,523
35,630
32,479
20,122
13,038
6,531
39,869
32,938
-4,479
-29,083
4,118
-63,072
-63,0724,118-29,083-4,47932,93839,8696,53113,03820,12232,47935,63059,52369,51374,890107,107140,189149,197135,610165,425138,488123,211150,935138,110
   Common Stock
138
140
142
145
148
149
151
152
153
153
155
158
161
163
165
187
22
278
287
393
402
403
405
40540340239328727822187165163161158155153153152151149148145142140138
   Retained Earnings 
41,620
47,929
17,147
29,530
50,713
31,254
43,071
33,048
0
0
0
-53,731
-79,258
-83,823
-99,896
-111,252
-119,584
-131,800
-141,489
-185,665
-212,116
-227,059
-249,017
-249,017-227,059-212,116-185,665-141,489-131,800-119,584-111,252-99,896-83,823-79,258-53,73100033,04843,07131,25450,71329,53017,14747,92941,620
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
126,720
128,508
130,229
134,171
132,522
127,736
173,062
175,820
182,514
184,404
0
0
00184,404182,514175,820173,062127,736132,522134,171130,229128,508126,72000000000000
   Treasury Stock00-1,773-1,721-1,680-1,671-1,643-8,432-14,334-14,106-13,792-13,636-13,620-13,558-13,495-13,433-13,214-13,214-110-110-110-1100
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
12
11
16
16
13
0
0
0
0
0
0
0
0000000131616111200000000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2022-12-31)

Gross Profit (+$)
totalRevenue31,838
Cost of Revenue-13,607
Gross Profit18,23118,231
 
Operating Income (+$)
Gross Profit18,231
Operating Expense-35,678
Operating Income-3,840-17,447
 
Operating Expense (+$)
Research Development703
Selling General Administrative20,098
Selling And Marketing Expenses0
Operating Expense35,67820,801
 
Net Interest Income (+$)
Interest Income0
Interest Expense-1,008
Other Finance Cost-0
Net Interest Income-1,008
 
Pretax Income (+$)
Operating Income-3,840
Net Interest Income-1,008
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-5,836-2,852
EBIT - interestExpense = -4,848
-21,929
-20,950
Interest Expense1,008
Earnings Before Interest and Taxes (EBIT)-3,840-4,828
Earnings Before Interest and Taxes (EBITDA)-3,558
 
After tax Income (+$)
Income Before Tax-5,836
Tax Provision-29
Net Income From Continuing Ops-5,865-5,865
Net Income-21,958
Net Income Applicable To Common Shares-21,958
 
Non-recurring Events
Discontinued Operations-16,093
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net-9881,008
 

Technical Analysis of Interpace
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Interpace. The general trend of Interpace is BULLISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Interpace's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (57.1%) Bearish trend (-57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Interpace Biosciences Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.5 < 1.5 < 2.006.

The bearish price targets are: 1.35 > 1.28 > 1.23.

Tweet this
Interpace Biosciences Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Interpace Biosciences Inc. The current mas is .

The long score for the Moving Averages is 11/14.
The longshort score for the Moving Averages is 8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Interpace Biosciences Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Interpace Biosciences Inc. The current macd is 0.01316829.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Interpace price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Interpace. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Interpace price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Interpace Biosciences Inc Daily Moving Average Convergence/Divergence (MACD) ChartInterpace Biosciences Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Interpace Biosciences Inc. The current adx is 35.20.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Interpace shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Interpace Biosciences Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Interpace Biosciences Inc. The current sar is 2.36470402.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Interpace Biosciences Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Interpace Biosciences Inc. The current rsi is 50.48. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
Interpace Biosciences Inc Daily Relative Strength Index (RSI) ChartInterpace Biosciences Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Interpace Biosciences Inc. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Interpace price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Interpace Biosciences Inc Daily Stochastic Oscillator ChartInterpace Biosciences Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Interpace Biosciences Inc. The current cci is -55.65711964.

Interpace Biosciences Inc Daily Commodity Channel Index (CCI) ChartInterpace Biosciences Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Interpace Biosciences Inc. The current cmo is -3.51648528.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Interpace Biosciences Inc Daily Chande Momentum Oscillator (CMO) ChartInterpace Biosciences Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Interpace Biosciences Inc. The current willr is -89.49416342.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Interpace Biosciences Inc Daily Williams %R ChartInterpace Biosciences Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Interpace Biosciences Inc.

Interpace Biosciences Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Interpace Biosciences Inc. The current atr is 0.14244574.

Interpace Biosciences Inc Daily Average True Range (ATR) ChartInterpace Biosciences Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Interpace Biosciences Inc. The current obv is -111,892.

Interpace Biosciences Inc Daily On-Balance Volume (OBV) ChartInterpace Biosciences Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Interpace Biosciences Inc. The current mfi is 73.58.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Interpace Biosciences Inc Daily Money Flow Index (MFI) ChartInterpace Biosciences Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Interpace Biosciences Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-01CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-15STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-19STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-03WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-01MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-09BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-23CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-08MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-27MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-04-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-16MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

Interpace Biosciences Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Interpace Biosciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.476
Ma 20Greater thanMa 501.501
Ma 50Greater thanMa 1001.329
Ma 100Greater thanMa 2001.194
OpenGreater thanClose1.450
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Interpace with someone you think should read this too:
  • Are you bullish or bearish on Interpace? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Interpace? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Interpace Biosciences Inc

I send you an email if I find something interesting about Interpace Biosciences Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Interpace Biosciences Inc.

Receive notifications about Interpace Biosciences Inc in your mailbox!